Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10495MR)

This product GTTS-WQ10495MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10495MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9890MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ11923MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ5118MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ3324MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ10643MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3819253
GTTS-WQ10247MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ10100MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ1083MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-838
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW